{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:06:09Z","timestamp":1785769569931,"version":"3.56.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Peripheral arterial disease (PAD) is a common vascular condition caused mainly by atherosclerosis that can cause ischemia and increase cardiovascular risk. Noninvasive imaging, such as Doppler ultrasonography, provides hemodynamic information but lack molecular insight. Integrin \u03b1v\u03b23 expression reflects angiogenesis in ischemic tissue and radiolabeled RGD peptides can be used to visualize this process noninvasively. This study prospectively assessed the diagnostic performance of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NODAGA-RGD PET\u2013computed tomography (CT) in patients with suspected or proven PAD and correlate the findings to clinical and Doppler findings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Thirty patients aged 26\u201387 years (23 males and 7 females, median age 52 years) presented with clinical or Doppler findings that were consistent with PAD underwent an imaging study with\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NODAGA-RGD PET\u2013CT 60\u2005\u00b1\u200515\u2005min following the injection of a radiotracer dose of 3\u20135\u2005mCi. Tracer uptake was visually rated on a four-point scale relative to liver and spleen activity and the maximum standardized uptake (SUV\n                      <jats:sub>max<\/jats:sub>\n                      ) was documented. Using the clinical and Doppler findings as gold standard diagnostic indices were calculated. An agreement analysis was performed using Cohen\u2019s \u03ba and McNemar\u2019s test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifteen patients had PAD and 15 had non-PAD (tumor-induced thrombosis \u2013 1, cellulitis \u2013 9, diabetic foot \u2013 3, arthritis \u2013 2).\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NODAGA-RGD PET\u2013CT was positive in 11 of 15 PAD patients (true positives) and negative in 15 of the 15 non-PAD patients (true negatives), with zero false positives and four false negatives. The sensitivity, specificity, and positive predictive values were 73.34%, 100%, and 100%, respectively. False negatives were primarily associated with acute ischemia lacking angiogenesis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NODAGA-RGD PET\u2013CT shows potential value and agreement with Doppler and clinical assessment for detecting PAD and may serve as a potential molecular imaging modality to evaluate angiogenesis and the disease extent as a complementary diagnostic imaging modality. Although RGD tracers have been explored for theranostic applications in oncology, the uptake levels observed in PAD in this study were generally low and currently do not support such applications. It also provides an evaluation of systemic vascularity outside of localized segments. Larger studies are warranted to validate its disease management implications.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002160","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:02:26Z","timestamp":1775815346000},"page":"986-993","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pilot feasibility study investigating 68Ga-NODAGA-RGD PET\u2013computed tomography molecular angiogenesis imaging in patients with peripheral arterial diseases: can it be of potential clinical value?"],"prefix":"10.1097","volume":"47","author":[{"given":"Vishwajeet","family":"Jadhav","sequence":"first","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe"},{"name":"Homi Bhabha National Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Verma","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe"},{"name":"Homi Bhabha National Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Chandak","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Shinde","sequence":"additional","affiliation":[{"name":"Department of Surgery, Seth GS Medical College and KEM Hospital\u2002and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dev","family":"Adhikari","sequence":"additional","affiliation":[{"name":"Department of Surgery, LTMG Hospital, Sion, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6607-2558","authenticated-orcid":false,"given":"Sandip","family":"Basu","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe"},{"name":"Homi Bhabha National Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"R1-20260708","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/01.CIR.71.3.510","article-title":"The prevalence of peripheral arterial disease in a defined population.","volume":"71","author":"Criqui","year":"1985","journal-title":"Circulation"},{"key":"R2-20260708","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/01.CIR.91.5.1472","article-title":"Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study.","volume":"91","author":"Hiatt","year":"1995","journal-title":"Circulation"},{"key":"R3-20260708","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1161\/01.CIR.0000137913.26087.F0","article-title":"Prevalence of and risk factors for peripheral arterial disease in the United States: results from the Nacional Health and Nutrition Examination Survey, 1999\u20132000.","volume":"110","author":"Selvin","year":"2004","journal-title":"Circulation"},{"key":"R4-20260708","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/1358863X9700200314","article-title":"The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease.","volume":"2","author":"Hirsch","year":"1997","journal-title":"Vasc Med"},{"key":"R5-20260708","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/0895-4356(92)90150-L","article-title":"The Edinburgh Claudication Questionare: an improved version of the WHO\/Rose Questionare for use in epidemiological surveys.","volume":"45","author":"Leng","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"R6-20260708","first-page":"42","article-title":"Self-administration of a questionare on chest pain and intermittent claudication.","volume":"3191","author":"Rose","year":"1977","journal-title":"Br J PrevSoc med"},{"key":"R7-20260708","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s00259-015-3259-3","article-title":"Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis.","volume":"43","author":"Bucerius","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-20260708","doi-asserted-by":"crossref","first-page":"887508","DOI":"10.3389\/fmed.2022.887508","article-title":"Overview of the RGD-based PET agents use in patients with cardiovascular diseases: a systematic review.","volume":"9","author":"Dietz","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R9-20260708","first-page":"2104","article-title":"Radiotracer imaging of peripheral vascular disease.","volume":"54","author":"Stacy","year":"2013","journal-title":"J Nucl Med"},{"key":"R10-20260708","first-page":"2459","article-title":"Clinical translation of integrin \u03b1v\u03b23-targeted RGD PET imaging in vascular diseases: current status and perspectives.","volume":"47","author":"Luo","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-20260708","doi-asserted-by":"crossref","first-page":"837952","DOI":"10.3389\/fonc.2022.837952","article-title":"Preliminary clinical application of RGD-containing peptides as PET radiotracers for imaging tumors.","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"R12-20260708","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13550-021-00815-5","article-title":"Imaging angiogenesis in atherosclerosis in large arteries with 68Ga-NODAGA-RGD PET\/CT: relationship with clinical atherosclerotic cardiovascular disease.","volume":"11","author":"Dietz","year":"2021","journal-title":"EJNMMI Res"},{"key":"R13-20260708","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2967\/jnumed.107.047423","article-title":"Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl1-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice.","volume":"49","author":"Jeong","year":"2008","journal-title":"J Nucl Med"},{"key":"R14-20260708","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1073\/pnas.0811757106","article-title":"Biodegradable dendritic positron emitting nanoprobes for the noninvasive imaging of angiogenesis.","volume":"106","author":"Almutairi","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"R15-20260708","first-page":"472","article-title":"Radiolabeled RGD uptake and alphav integrin expression is enhanced in ischemic murine hindlimbs.","volume":"46","author":"Lee","year":"2005","journal-title":"J Nucl Med"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:15:25Z","timestamp":1785766525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002160","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"2026-01-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}